Patents Assigned to Sprout Pharmaceuticals, Inc.
  • Treating sexual desire disorders with flibanserin
    Patent number: 11058683
    Abstract: The invention relates to the use of flibanserin, or a pharmaceutically acceptable acid addition salt thereof, for the treatment of disorders of sexual desire.
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: July 13, 2021
    Assignee: Sprout Pharmaceuticals, Inc.
    Inventors: Franco Borsini, Kenneth Robert Evans
  • Use of Flibanserin in the treatment of obesity
    Patent number: 10874668
    Abstract: The invention relates to compositions for the treatment of obesity and related diseases comprising a) an active substance being not flibanserin, selected from the group consisting of active substances for the treatment of obesity and obesity related diseases and b) flibanserin, optionally in the form of pharmacologically acceptable acid addition salts thereof.
    Type: Grant
    Filed: June 3, 2019
    Date of Patent: December 29, 2020
    Assignee: Sprout Pharmaceuticals, Inc.
    Inventors: Angelo Ceci, Marcus Schindler
  • Treating sexual desire disorders with flibanserin
    Patent number: 10675280
    Abstract: The invention relates to the use of flibanserin, or a pharmaceutically acceptable acid addition salt thereof, for the treatment of disorders of sexual desire.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: June 9, 2020
    Assignee: Sprout Pharmaceuticals, Inc.
    Inventors: Franco Borsini, Kenneth Robert Evans
  • Treatment of vasomotor symptoms
    Patent number: 10596170
    Abstract: The invention relates to a method for the treatment of vasomotor symptoms comprising the administration of a therapeutically effective amount of flibanserin.
    Type: Grant
    Filed: November 26, 2018
    Date of Patent: March 24, 2020
    Assignee: Sprout Pharmaceuticals, Inc.
    Inventors: Vladimir Hanes, Anna Elisabeth Verbeek
  • Use of flibanserin in the treatment of obesity
    Patent number: 10335407
    Abstract: The invention relates to compositions for the treatment of obesity and related diseases comprising a) an active substance being not flibanserin, selected from the group consisting of active substances for the treatment of obesity and obesity related diseases and b) flibanserin, optionally in the form of pharmacologically acceptable acid addition salts thereof.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: July 2, 2019
    Assignee: Sprout Pharmaceuticals, Inc.
    Inventors: Angelo Ceci, Marcus Schindler
  • Treating sexual desire disorders with flibanserin
    Patent number: 10307420
    Abstract: The invention relates to the use of flibanserin, or a pharmaceutically acceptable acid addition salt thereof, for the treatment of disorders of sexual desire.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: June 4, 2019
    Assignee: Sprout Pharmaceuticals, Inc.
    Inventors: Franco Borsini, Kenneth Robert Evans
  • Use of Flibanserin in the Treatment of Obesity
    Publication number: 20180015084
    Abstract: The invention relates to compositions for the treatment of obesity and related diseases comprising a) an active substance being not flibanserin, selected from the group consisting of active substances for the treatment of obesity and obesity related diseases and b) flibanserin, optionally in the form of pharmacologically acceptable acid addition salts thereof.
    Type: Application
    Filed: July 31, 2017
    Publication date: January 18, 2018
    Applicant: Sprout Pharmaceuticals, Inc.
    Inventors: Angelo Ceci, Marcus Schindler
  • Treating sexual desire disorders with flibanserin
    Patent number: 9782403
    Abstract: The invention relates to the use of fibanserin, or a pharmaceutically acceptable acid addition salt thereof, for the treatment of disorders of sexual desire.
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: October 10, 2017
    Assignee: Sprout Pharmaceuticals, Inc.
    Inventors: Franco Borsini, Kenneth Robert Evans
  • Flibanserin for the treatment of urinary incontinence and related diseases
    Patent number: 9763936
    Abstract: The invention relates to the use of Flibanserin for the treatment or prevention of urinary incontinence and related diseases. In a further embodiment, the instant invention is directed to pharmaceutical combinations comprising flibanserin as one active ingredient in combination with at least one additional active ingredient for the treatment or prevention of urinary incontinence and related diseases.
    Type: Grant
    Filed: July 27, 2015
    Date of Patent: September 19, 2017
    Assignee: Sprout Pharmaceuticals, Inc.
    Inventors: Ramiro Castro, Angelo Ceci
  • Use of flibanserin in the treatment of obesity
    Patent number: 9730927
    Abstract: The invention relates to compositions for the treatment of obesity and related diseases comprising a) an active substance being not flibanserin, selected from the group consisting of active substances for the treatment of obesity and obesity related diseases and b) flibanserin, optionally in the form of pharmacologically acceptable acid addition salts thereof.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: August 15, 2017
    Assignee: Sprout Pharmaceuticals, Inc.
    Inventors: Angelo Ceci, Marcus Schindler
  • Salts
    Patent number: 9546141
    Abstract: The present invention relates to new crystalline salt forms of flibanserine which have valuable pharmacological properties, to a process for their manufacture, to pharmaceutical formulations containing them and to their use as medicament.
    Type: Grant
    Filed: September 12, 2014
    Date of Patent: January 17, 2017
    Assignee: Sprout Pharmaceuticals, Inc.
    Inventors: Jaroslaw Mazurek, Mihaela Pop
  • Treating sexual desire disorders with flibanserin
    Patent number: 9468639
    Abstract: The invention relates to the use of flibanserin, or a pharmaceutically acceptable acid addition salt thereof, for the treatment of disorders of sexual desire.
    Type: Grant
    Filed: March 6, 2015
    Date of Patent: October 18, 2016
    Assignee: Sprout Pharmaceuticals, Inc.
    Inventors: Franco Borsini, Kenneth Robert Evans
  • Use of Flibanserin in the Treatment of Obesity
    Publication number: 20160136161
    Abstract: The invention relates to compositions for the treatment of obesity and related diseases comprising a) an active substance being not flibanserin, selected from the group consisting of active substances for the treatment of obesity and obesity related diseases and b) flibanserin, optionally in the form of pharmacologically acceptable acid addition salts thereof.
    Type: Application
    Filed: November 13, 2015
    Publication date: May 19, 2016
    Applicant: Sprout Pharmaceuticals, Inc.
    Inventors: Angelo Ceci, Marcus Schindler
  • Salts
    Publication number: 20150126524
    Abstract: The present invention relates to new crystalline salt forms of flibanserine which have valuable pharmacological properties, to a process for their manufacture, to pharmaceutical formulations containing them and to their use as medicament.
    Type: Application
    Filed: September 12, 2014
    Publication date: May 7, 2015
    Applicant: SPROUT PHARMACEUTICALS, INC.
    Inventors: Jaroslaw Mazurek, Mihaela Pop
  • Method for the treatment of premenstrual and other female sexual disorders
    Publication number: 20150111898
    Abstract: The invention relates to a method for the treatment of premenstrual and other female sexual disorders comprising the administration of a therpeutically effective amount of flibanserin.
    Type: Application
    Filed: September 3, 2014
    Publication date: April 23, 2015
    Applicant: Sprout Pharmaceuticals, Inc.
    Inventor: Robert Pyke
  • Use of Flibanserin in the Treatment of Obesity
    Publication number: 20150072994
    Abstract: The invention relates to a method for the treatment of obesity and related diseases comprising the administration of a therapeutically effective amount of Flibanserin.
    Type: Application
    Filed: July 21, 2014
    Publication date: March 12, 2015
    Applicant: SPROUT PHARMACEUTICALS, INC.
    Inventors: Angelo Ceci, Marcus Schindler
  • Sulfated Benzimidazolone Derivatives Having Mixed Serotonine Receptor Affinity
    Publication number: 20150011564
    Abstract: The present invention pertains to a compound of formula (I) wherein R1, R2, R3, and R4 are each hydrogen or sulfate monoester with the proviso that R1, R2, R3, and R4 cannot simultaneously be hydrogen, processess for their preparation and their use as pharmaceuticals in the treatment of CNS disorders.
    Type: Application
    Filed: May 8, 2014
    Publication date: January 8, 2015
    Applicant: Sprout Pharmaceuticals, Inc.
    Inventors: Astrid Volz, Ralf Lotz, Fabio Paleari
  • USE OF A POLYMORPH OF FLIBANSERIN FOR TREATING DISEASE
    Publication number: 20150005316
    Abstract: The invention relates to the polymorph A of flibanserin, to a technical process for the preparation thereof, as well as to the use thereof for preparing medicaments.
    Type: Application
    Filed: May 5, 2014
    Publication date: January 1, 2015
    Applicant: SPROUT PHARMACEUTICALS, INC.
    Inventors: Carlo Bombarda, Enrica Dubini, Antoine Ezhaya
  • Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
    Publication number: 20140329827
    Abstract: The invention relates to the use of flibanserin for the preparation of a medicament for the treatment of pre-menopausal Sexual Desire Disorders.
    Type: Application
    Filed: March 4, 2014
    Publication date: November 6, 2014
    Applicant: Sprout Pharmaceuticals, Inc.
    Inventors: Stephane Pollentier, Robert E. Pyke
  • Use of flibanserin in the treatment of obesity
    Patent number: 8785458
    Abstract: The invention relates to a method for the treatment of obesity and related diseases comprising the administration of a therapeutically effective amount of Flibanserin.
    Type: Grant
    Filed: July 16, 2012
    Date of Patent: July 22, 2014
    Assignee: Sprout Pharmaceuticals, Inc.
    Inventors: Angelo Ceci, Marcus Schindler